Company profile for Newleos Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Newleos Therapeutics is pioneering next-generation therapies for mental health conditions, focusing on anxiety and substance use disorders—two major areas of unmet medical need. Our clinical-stage pipeline, licensed from Roche, includes oral small molecules targeting GABAA-γ1, V1a, TAAR1, and GABAA-α5, with broad potential in anxiety, substance use, and cognitive impairment. Co-founded by Longwood Fund, Dr. Federico Bologn...
Newleos Therapeutics is pioneering next-generation therapies for mental health conditions, focusing on anxiety and substance use disorders—two major areas of unmet medical need. Our clinical-stage pipeline, licensed from Roche, includes oral small molecules targeting GABAA-γ1, V1a, TAAR1, and GABAA-α5, with broad potential in anxiety, substance use, and cognitive impairment. Co-founded by Longwood Fund, Dr. Federico Bolognani, and Dr. William Martin, Newleos is dedicated to delivering first- and best-in-class treatments for neuropsychiatric disorders.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
800 Boylston St, Ste 1715 Boston, MA 02199
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Natural Product Expo West

Natural Product Expo West

Not Confirmed

envelop Contact Supplier

Natural Product Expo West

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20260106866335/en/Newleos-Therapeutics-Announces-Dosing-of-First-Participant-in-SOAR-Phase-2-Study-of-NTX-1472-for-Social-Anxiety-Disorder

BUSINESSWIRE
06 Jan 2026

https://www.pharmiweb.com/press-release/2025-10-21/newleos-therapeutics-appoints-timothy-noyes-as-president-and-chief-executive-officer

PHARMIWEB
21 Oct 2025

https://www.pharmiweb.com/press-release/2025-10-15/newleos-therapeutics-ceo-david-donabedian-recognized-by-goldman-sachs-as-one-of-the-most-exceptional

PHARMIWEB
15 Oct 2025

https://www.businesswire.com/news/home/20250930298807/en/Newleos-Therapeutics-Announces-Clinical-Progress-Across-Neuropsychiatric-Pipeline

BUSINESSWIRE
30 Sep 2025

https://www.businesswire.com/news/home/20250909945977/en/Newleos-Therapeutics-Announces-Poster-Presentation-to-be-Featured-at-the-2025-World-Congress-of-Biological-Psychiatry

BUSINESSWIRE
09 Sep 2025

https://www.businesswire.com/news/home/20250723893290/en/Newleos-Therapeutics-Appoints-Stephen-Brannan-to-Board-of-Directors-and-Announces-NTX-1955-Clinical-Progress-in-Generalized-Anxiety-Disorder

BUSINESSWIRE
23 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty